{"product_id":"organogenesis-five-forces-analysis","title":"Organogenesis Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cporganogenesis faces moderate supplier power and high competitive rivalry in regenerative medicine while buyer sophistication regulatory hurdles shape pricing market access.\u003e\n\u003cpthis brief snapshot only scratches the surface. unlock full porter five forces analysis to explore organogenesis competitive dynamics market pressures and strategic advantages in detail.\u003e\n\u003c\/pthis\u003e\u003c\/porganogenesis\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Biological Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganogenesis depends on niche biological inputs—neonatal skin cells and specialized bovine collagen—that meet strict FDA and ISO quality rules, leaving roughly 3–5 qualified suppliers globally as of 2025.\u003c\/p\u003e\n\u003cp\u003eSupplier concentration raises risk: a 10–20% price rise or a single-source disruption could lift COGS materially—here’s quick math: a 15% raw-material hike versus 2024 COGS would cut gross margin by ~4–6 percentage points on product lines. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers in regenerative medicine must follow strict Good Manufacturing Practices and FDA rules, raising entry barriers; as of 2024, ~85% of advanced wound-care suppliers report FDA-related validation costs exceeding $1.2M per product, boosting incumbent leverage.\u003c\/p\u003e\n\u003cp\u003eFor Organogenesis, switching vendors risks months of re-validation and potential 510(k) or BLA re-submissions, which can delay product supply and add millions in compliance costs, so existing compliant suppliers hold substantial bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Amniotic Tissue Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganogenesis relies on a small set of recovery agencies for human placental tissue for Affinity and NuShield; in 2024 roughly 60–70% of compliant birth-tissue supply in the US came from fewer than 12 agencies, concentrating leverage.\u003c\/p\u003e\n\u003cp\u003eThese agencies set prices and contract terms; a 2023 industry survey showed supplier-driven price increases of 8–12% YoY and contract tenors favoring suppliers (3–5 year minimums with steep renewal escalators).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Technical Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe specialized cleanroom systems and proprietary bioreactors used in Organogenesis’s bioactive wound-healing production create high switching costs—replacing a line can cost tens of millions and months of downtime; a 2024 BioProcess survey found 62% of biologics makers cite equipment transition as the top capex risk.\u003c\/p\u003e\n\u003cp\u003eThis lock-in boosts supplier power over multi-year maintenance, parts pricing, and staged upgrades, enabling manufacturers to extract premium service margins and favorable contract terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital cost: tens of millions per line\u003c\/li\u003e\n\u003cli\u003eDowntime: months to qualify new equipment\u003c\/li\u003e\n\u003cli\u003e62% cite transition as top capex risk (BioProcess 2024)\u003c\/li\u003e\n\u003cli\u003eSuppliers gain leverage on maintenance and upgrade pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Specialized Labor Scarcity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of specialized lab services and CROs hold strong leverage over Organogenesis because niche regenerative-medicine skills are scarce; BioSpace reported a 28% U.S. biotech technical hiring gap in 2024, and specialized CRO rates rose 12–20% year-over-year through 2025.\u003c\/p\u003e\n\u003cp\u003eThis labor-driven scarcity lets providers charge premiums for R\u0026amp;D-critical services, raising Organogenesis’s COGS and extending timelines when headcount shortages hit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% U.S. biotech technical hiring gap (2024)\u003c\/li\u003e\n\u003cli\u003eCRO rate inflation 12–20% YoY (2023–2025)\u003c\/li\u003e\n\u003cli\u003eHigher COGS and schedule risk for Organogenesis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganogenesis at risk: concentrated suppliers, costly validation, margin squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganogenesis faces high supplier power: 3–5 qualified biological input vendors (2025), 60–70% birth-tissue supply from \u0026lt;12 agencies (2024), and equipment replacements costing tens of millions with months downtime; a 15% raw-material price shock would cut gross margin ~4–6 pts vs 2024. CRO rate inflation 12–20% (2023–2025) and FDA validation \u0026gt;$1.2M\/product (2024) boost supplier leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers (global, 2025)\u003c\/td\u003e\n\u003ctd\u003e3–5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBirth-tissue share from \u0026lt;12 agencies (2024)\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material shock impact\u003c\/td\u003e\n\u003ctd\u003e15% → −4–6pp gross margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO rate inflation (2023–2025)\u003c\/td\u003e\n\u003ctd\u003e12–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA validation cost (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.2M\/product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Organogenesis that uncovers competitive drivers, supplier and buyer power, entry barriers, substitutes, and disruptive threats to inform strategic decisions and investor materials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter's Five Forces snapshot for Organogenesis that highlights competitive pressures and strategic levers—ideal for quick boardroom decisions and slide-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of CMS Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Centers for Medicare and Medicaid Services (CMS) hold outsized customer power by setting reimbursement for advanced wound care; Medicare accounts for roughly 40% of payer mix in chronic wound cases, so fee-schedule cuts hit volumes fast.\u003c\/p\u003e\n\u003cp\u003eChanges to the 2025 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System lowered several skin substitute codes by ~8–12%, shifting pricing leverage to CMS and pressuring Organogenesis’ ASPs and adoption rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeverage of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge gpos and integrated delivery networks represent over of hospital contracting volume in the us letting them demand double-digit discounts strict rebate terms from device biologics suppliers. organogenesis must secure gpo formulary placement to access wound-care procurement often conceding lower per-unit margins contracts show average vs list. losing would cut reachable market share materially.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital consolidation has produced mega-health systems with centralized procurement; in the US, 60% of hospitals were part of multi-hospital systems by 2023, raising buyer scale and negotiating clout.\u003c\/p\u003e\n\u003cp\u003eThese buyers run value-based procurement, using outcomes-versus-cost analytics; Organogenesis must supply RCT-level evidence and real-world cost-per-healed wound data to win contracts.\u003c\/p\u003e\n\u003cp\u003eAs clinics merge into systems, local negotiating power falls; single-system contracts can represent 100s of sites and \u0026gt;$10M annual spend, pressuring Organogenesis on price and value guarantees.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Clinical Evidence for Decision Making\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpphysicians and hospital committees now require randomized head-to-head trials before adopting costly regenerative products a survey found of us hospitals demand comparative evidence for procurement decisions.\u003e\n\u003cpif competitors show faster healing or lower total cost of care buyers shift quickly cutting organogenesis share real-world wound-care studies in reported such gaps.\u003e\n\u003cpthis data-driven market lets customers press for price cuts or bundled clinical support with of large health systems negotiating outcome-based contracts in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% hospitals demand comparative trials\u003c\/li\u003e\n\u003cli\u003e20–40% faster healing drives switching\u003c\/li\u003e\n\u003cli\u003e15–30% lower total cost prompts pivots\u003c\/li\u003e\n\u003cli\u003e55% negotiate outcome-based contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pif\u003e\u003c\/pphysicians\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in Outpatient Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn outpatient wound care, clinics with tight margins view advanced biologics like PuraPly through the cost-to-reimbursement lens: if reimbursement covers only 60–80% of list price, many switch to cheaper acellular substitutes to preserve profitability.\u003c\/p\u003e\n\u003cp\u003eThis pressure forces Organogenesis to match or undercut competitors; in 2024, ~45% of US outpatient wound centers reported prioritizing lower-cost products when reimbursement fell below target.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh price sensitivity: reimbursement gap 20–40%\u003c\/li\u003e\n\u003cli\u003eClinics switch to acellular options if margins shrink\u003c\/li\u003e\n\u003cli\u003e2024: ~45% centers prioritize lower-cost products\u003c\/li\u003e\n\u003cli\u003eOrganogenesis must keep aggressive pricing to retain share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers Hold the Power: Medicare Cuts, GPO Discounts \u0026amp; Outcome Contracts Squeeze Prices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (CMS, GPOs, IDNs, clinics) wield strong leverage: Medicare ~40% wound payer mix and 2025 fee cuts (-8–12%) lower ASPs; GPO\/IDN contracts cover ~70% procurement with typical discounts 15–30%; 60% hospitals in systems (2023); 68% require head-to-head trials; 55% use outcome-based contracts (2024); 45% outpatient centers favor lower-cost products when reimbursement covers ≤80%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 fee cuts\u003c\/td\u003e\n\u003ctd\u003e-8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO\/IDN reach\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO discounts\u003c\/td\u003e\n\u003ctd\u003e15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals in systems (2023)\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRequire trials (2024)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutcome contracts (2024)\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient cost-sensitivity (2024)\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eOrganogenesis Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Organogenesis Porter's Five Forces analysis you'll receive after purchase—no placeholders or mockups; it's the finished, professionally formatted document ready for immediate download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746663477625,"sku":"organogenesis-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organogenesis-five-forces-analysis.png?v=1772190723","url":"https:\/\/matrixbcg.com\/products\/organogenesis-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}